We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Enveric Biosciences Inc (ENVB) USD0.01

Sell:$0.70 Buy:$0.73 Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Enveric Biosciences Inc. (Enveric) is an early-development-stage biosciences company. Enveric focuses on developing evidence-based prescription products and combination therapies containing cannabinoids to address unmet needs in cancer care. It enhances the lives of patients suffering from cancer, by developing palliative and supportive care products for people suffering from side effects of cancer and cancer treatment such as pain or skin irritation. Enveric pipeline product include cannabinoid therapies, Cannabidiol and (CBD) and cannabigerol (CBG) for hard-to-treat cancers, including glioblastoma multiforme (GBM). Cannabinoid is derived from hemp, other botanical sources, and synthetic materials containing no tetrahydrocannabinol (THC) used in therapeutic formulations.

Contact details

4851 Tamiami Trail N, Suite 200
United States
+1 (239) 3021707

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$23.50 million
Shares in issue:
31.38 million
United States
US dollar

Key personnel

  • David Johnson
    Executive Chairman of the Board
  • Avani Kanubaddi
    President, Chief Operating Officer
  • Joseph Tucker
    Chief Executive Officer, Director
  • Carter Ward
    Chief Financial Officer
  • Jillian Hagel
    Chief Technology Officer
  • Peter Facchini
    Chief Scientific Officer
  • Bob Dagher
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.